

S4 Table. JIKI trial: Baseline and follow-up characteristics in adult and adolescents who died and in those who survived

	N	Died (n=51)		Survived (n=48)		p
Baseline						
Sex, female, n (%)	99	31	(61)	32	(67)	0.68
Age (years) , median (IQR)	99	40	(28-55)	31	(19-47)	0.05
Mode of contamination, n (%)	99					0.25
Funerals		30	(59)	20	(42)	
Contact with EVD patient		20	(39)	24	(50)	
Unknown		1	(2)	4	(8)	
RT-PCR Ct value, median (IQR)	99	17.7	(16.3-19.5)	23.8	(21.0-26.9)	<0.001
Viral load (log ₁₀ copies/ml), median (IQR)	84	8.4	(7.8-9.1)	6.4	(5.8-7.5)	<0.001
Positive malaria rapid test, n (%)	97	5	(10)	6	(13)	0.75
Creatinine (μmol/L), median (IQR)	91	285	(134-521)	108	(79-165)	<0.001
BUN (mmol/l), median (IQR)	91	14.6	(8.4-25.9)	6.8	(4.3-12.2)	<0.001
BUN:creatinine ratio, median (IQR)	91	0.05	(0.04-0.07)	0.06	(0.04-0.08)	0.22
AST (IU/l), median (IQR)	46	1312	(232-2000)	374	(139-1002)	0.12
ALT (IU/ l), median (IQR)	54	344	(160-536)	130	(74-320)	0.05
CK (IU/l), median (IQR)	53	2119	(735-4099)	1176	(590-2977)	0.31
Bilirubin (mg/dl), median (IQR)	51	12.0	(9.0-19.0)	10.5	(9.0-11.5)	0.08
Amylase (IU/l), median (IQR) ¶	53	133.0	(96.0-185.0)	92.0	(71.0-141.0)	0.11
CRP (mg/l), median (IQR) ¶	51	29.5	(14.2-58.6)	15.2	(5.0-37.4)	0.11
Albumin (g/l), median (IQR) ¶	53	30.0	(29.0-36.0)	30.0	(27.5-34.5)	0.93
Sodium (mmol/L), median (IQR)	86	132	(128-135)	132	(129-136)	0.92
Potassium (mmol/L), median (IQR)	84	3.8	(3.5-4.6)	3.9	(3.4-4.3)	0.87
Glucose (mmol/L), median (IQR)	83	5.75	(4.42-6.80)	5.8	(4.88-6.99)	0.72
Treatment						
Time from first symptoms to favipir. initiation (days), median (IQR)	99	5	(3-7)	5	(3-7)	0.53
IV fluid rehydration, n (%)	99	50	(98)	41	(85)	0.03

S4 Table (continued). JIKI trial: Baseline and follow-up characteristics in adult and adolescents who died and in those who survived

	N	Died (n=51)		Survived (n=48)		<i>p</i>
<i>Signs and symptoms during hospital stay</i>						
Maximal temperature (°C), median (IQR)	99	39.3	(38.8-40.0)	39.1	(38.1-39.9)	0.17
Vomiting, maximal grade, n (%)	99					0.16
0		9	18%	3	6%	
1		28	55%	34	71%	
2		10	20%	6	13%	
3		4	8%	1	2%	
Diarrhea, maximal grade, n (%)	99					0.003
0		0	0%	2	4%	
1		6	12%	18	38%	
2		16	31%	14	29%	
3		29	57%	14	29%	
Impaired consciousness, maximal grade, n (%)	99					<0.001
0		20	39%	42	88%	
1		25	49%	5	10%	
2		3	6%	1	2%	
3		3	6%	0	0%	
Any pain, maximal grade, n (%)	99					<0.001
0		1	2%	0	0%	
1		26	51%	44	92%	
2		18	35%	3	6%	
3		6	12%	1	2%	
Any hemorrhage, at least once, n (%)	99	36	71%	21	44%	0.01
Hiccup, at least once, n (%)	99	8	16%	9	19%	0.79
Dehydration, at least once, n (%)	99	41	80%	30	63%	0.07
Icterus, n (%)	99	6	12%	4	8%	0.74
Edema, at least once, n (%)	99	7	14%	7	15%	1.00

Footnotes to S4 Table:

N=number of patients with available value. For biochemical tests, all four trial centers, systematically measured creatinine, BUN, sodium, potassium and glucose. Three of the four centers (Gueckedou, Macenta, Conakry), also measured serum AST, ALT, total bilirubin, amylase, albumin, CK and C-RP.

BUN: Blood urea nitrogen ; AST: aspartate aminotransferase. ALT: alanine aminotransferase; CK: creatine phosphokinase; CRP: C-reactive protein; IU: international units. Favipir.: favipiravir.

1st sympt-FVP : time between the onset of first symptom and first dose of favipiravir

Signs and symptoms were documented twice a day during the overall hospital stay. Diarrhea, consciousness, pain, and vomiting were graded 0 to 3; for other signs/symptoms, only the presence or absence of the sign/symptom (yes/no) was noted.